Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

1677P - Risk factors predicting immune checkpoint inhibitors (ICIs) toxicity using machine learning computer algorithm

Date

10 Sep 2022

Session

Poster session 06

Topics

Translational Research;  Immunotherapy

Tumour Site

Presenters

Roy Holland

Citation

Annals of Oncology (2022) 33 (suppl_7): S758-S771. 10.1016/annonc/annonc1078

Authors

R. Holland1, K. Miron2, T.G. Goshen - Lago1, N. Gordon1, A. Zer1, I. Ben-Aharon1

Author affiliations

  • 1 Division Of Oncology, Rambam Health Care Campus, 3109601 - Haifa/IL
  • 2 Division Of Information Technology, Rambam Health Care Campus, 3109601 - Haifa/IL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1677P

Background

Although ICIs revolutionized modern oncology, a significant challenge remains to minimize immune related adverse events (irAEs), and subsequent financial burden due to treatment delay and hospitalization. There is a paucity of data about predicting biomarkers for ICI-related toxicity. In this study we aimed to use machine learning (ML) algorithms to study the profile of ICI toxicity.

Methods

A computer algorithm was developed using SAP Business Objects BI Platform 4.2 to extract electronic medical records (EMR) of patients receiving ICIs and identify irAEs. To avoid potential confounding effects, the study included only patient receiving ICIs without concurrent chemotherapy, biological or hormonal therapy or radiotherapy during the study period. The algorithm used all available data on each patient; Namely, structured data (e.g., numeric lab results) and unstructured data (e.g., patient notes written by the treating physician). The code mapped irAEs drawn from the structured database, as well as irAEs drawn from medical notes using ML models in Natural Language Processing (NLP) with MDCLONE Studio V1.1.2 tool. Association between variables and irAEs were assessed using chi-squared and t tests.

Results

The study cohort included 1617 patients with solid tumors who received ICIs between the years 2010-2021 in the Division of Oncology in Rambam Health Care Campus. 1104 (68%) were men, mean age was 69 years. 910 (56%) patients developed grade 3&4 irAEs during and after the ICIs treatment. Gender, BMI and pretreatment derived neutrophil-to-lymphocytes ratio (dNLR) were not associated with higher irAEs in the general cohort. Younger age and PDL-1/CTLA-4 combination were found to be associated with higher irARs rates (P=0.001 and P<.001, respectively). In subgroup analysis, young age was found to be associated with hepatotoxicity and hematologic irAEs (P<.001 and P=0.01, respectively), female gender was associated with endocrine toxicity (P=0.024) and high BMI and low dNLR were associated with renal irAEs (P=0.001 and P=0.029, respectively).

Conclusions

Using ML tools in real-world data setting, several key characteristics were identified to be correlated with high tendency of irAEs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.